Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population
Open Access
- 29 January 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 56 (9) , 1330-1339
Abstract
Background. The nonnucleoside reverse transcriptase inhibitor nevirapine is the cornerstone of treatment for human immunodeficiency virus (HIV) in many sub-Saharan African countries. However, nevirapine is associated with a 6%–10% risk of developing a hypersensitivity reaction, with different phenotypes, including the blistering conditions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Our aim was to identify predictive human leukocyte antigen (HLA) markers that are associated with nevirapine hypersensitivity. Methods. We identified 117 HIV-infected Malawian adults with nevirapine hypersensitivity (15 drug-induced liver injury [DILI], 33 SJS/TEN, 20 hypersensitivity syndrome, and 46 nevirapine-induced rash plus 3 with both DILI and SJS phenotype) and 155 age-, sex- and ethnicity-matched nevirapine-exposed controls. HLA typing for 5 loci (A, B, C, DRB1, and DQB1) was undertaken using a sequence-based high-resolution protocol. Logistic regression analysis included CD4+ cell count as a covariate. Results. HLA-C*04:01 was found to markedly increase the risk for SJS (odds ratio [OR] = 17.52; 95% confidence interval, 3.31–92.80) and all hypersensitivity phenotypes (OR = 2.64; 95% CI, 1.13–6.18) when compared to the baseline rare allele group in a binary logistic regression model. The OR for absolute risk of SJS/TEN associated with carriage of HLA-C*04:01 was 5.17 (95% CI, 2.39–11.18). Positive predictive value was 2.6% and negative predictive value was 99.2%. In addition, a number of alleles within the HLA-DQB1 loci protected against nevirapine-induced hypersensitivity phenotypes. Conclusions. Our study has identified HLA-C*04:01 carriage as a risk factor for nevirapine-induced SJS/TEN in a Malawian HIV cohort. Validation of these findings in a larger cohort of patients and mechanistic investigation of the pathogenesis are required.Keywords
This publication has 42 references indexed in Scilit:
- Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoireProceedings of the National Academy of Sciences, 2012
- Incidence of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in an HIV CohortAmerican Journal of Clinical Dermatology, 2012
- Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descentAIDS, 2011
- HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patientsJournal of Pharmacology and Pharmacotherapeutics, 2011
- HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in EuropeansNew England Journal of Medicine, 2011
- Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated Applications of NMR and Mass SpectrometriesDrug Metabolism and Disposition, 2010
- HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patientsAIDS Research and Therapy, 2009
- Discontinuation of Nevirapine Because of Hypersensitivity Reactions in Patients with Prior Treatment Experience, Compared with Treatment-Naive Patients: The ATHENA Cohort StudyClinical Infectious Diseases, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- Toxic epidermal necrolysis (Lyell syndrome)Journal of the American Academy of Dermatology, 1990